Puretech-backed Karuna makes Nas­daq de­but with $89M IPO

Bet­ting on the po­ten­tial of two old­er drugs to fight Alzheimer’s and schiz­o­phre­nia — Boston-based Karuna Ther­a­peu­tics has priced its up­sized ini­tial pub­lic of­fer­ing in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.